Ischemic events after initiation of steroid therapy in giant cell arteritis;Accidents vasculaires encephaliques precoces apres instauration d'une corticotherapie au cours de la maladie de horton

Revue de Medecine Interne

Volumn 21, Issue 6, 2000, Pages 550-554

  Paccalin, M ^a,b   Amoura, Z ^a   Roblot, P ^b   Godeau, P ^a   Becq Giraudon, B ^b   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Giant cell arteritis; Ischemic event; Steroid therapy

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID;

ADULT; ARTERIOSCLEROSIS; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; GIANT CELL ARTERITIS; HUMAN; ISCHEMIA; PRESCRIPTION; TEMPORAL ARTERITIS; AGED; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MIDDLE AGED;

ADRENAL CORTEX HORMONES; AGED; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MIDDLE AGED; TEMPORAL ARTERITIS;

EID: 0034212748     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)89232-2     Document Type: Article

References (39)

1. Wilkinson IMS, Russell RWR. Arteries of the head and neck in giant cell arteritis: A pathological study to show the pattern of arterial involvement. Arch Neurol 1972 ; 27 : 378-91.
2. Mehler MF, Rabinowich L. The clinical neuro-ophthalmologic spectrum of temporal arteritis. Am J Med 1988 ; 85 : 839-44.
3. Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis: Clinical characteristics and prognosis for vision. Ophthalmology 1994 ; 101 : 1779-85.
4. Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997 ; 36 : 251-4.
5. Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998 ; 41 : 26-32.
6. Reich KA, Giansiracusa DF, Strongwater SL. Neurologic manifestations of giant cell arteritis. Am J Med 1990 ; 89 : 67-72.
7. Neish PR, Sergent JS. Giant cell arteritis: A case with unusual neurologic manifestations and a normal sedimentation rate. Arch Intern Med 1991 ; 151 : 378-80.
8. Lie JT, Tokugawa DA. Bilateral lower limb gangrene and stroke as initial manifestations of systemic giant cell arteritis in an African-American. J Rheumatol 1995 ; 22 : 363-6.
9. Small P. Giant cell arteritis presenting as a bilateral stroke. Arthritis Rheum 1984 ; 27 : 819-21.
10. Caselli RJ, Hunder GG, Whisnart JP. Neurologic disease in biopsyproven giant cell (temporal arteritis). Neurology 1988 ; 38 : 352-9.
11. Caselli RJ. Giant cell (temporal) arteritis: A treatable cause of multi-infarct dementia. Neurology 1990 ; 40 : 753-5.
12. Ely GM. Giant cell arteritis complicated by multi-infarct dementia. J Clin Rheumatol 1998 ; 4 : 209-15.
13. Cooke WT, Cloake PCP, Govan ADT, Colbaeck JC. Temporal arteritis: A general vascular disease. Q J Med 1946 ; 15 : 47-75.
14. Bruce GM. Temporal arteritis as a cause of visual loss: Review of the literature and report of a case. Am J Ophthalmol 1950 ; 33 : 1568-73.
15. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: Results in fifty-five cases in which lesion was proved at biopsy. JAMA 1957 ; 163 : 821-7.
16. Hugod C, Scheibel M. Temporal arteritis. Progressive affection of vision during high-level corticosteroid therapy. Acta Med Scand 1979 ; 205 : 445-6.
17. Jouquan J, Mottier D, Cleuziou A, Pennec Y, Baccino E, Bergeret G, et al. Accidents vasculaires cérébraux précoces au cours de maladies de Horton traitées. Ann Méd Interne 1984 ; 135 : 526-9.
18. Ponge T, Barrier J, Mottier D, Jouquan J, Forgeau Y, Fève JR, et al. Les accidents vasculaires cérébraux au cours de la maladie de Horton. Sem HôP Paris 1984 ; 33 : 2365-70.
19. Chadenas D, Picon L, Roux C, Gauvain JB, Maitre F, Buzacoux J, et al. Paraplégie flasque de survenue brutale. Accident du traitement corticoïde de la maladie de Horton ? [lettre]. Presse MéD 1986 ; 15 : 845.
20. Collazos J, Garcia-Monco C, Martin A, Rodriguez J, Gomez MA. Multiple strokes after initiation of steroid therapy in giant cell arteritis. Postgrad Med J 1994 ; 70 : 228-30.
21. Khalaf K, Pages M, Blard JM, Labauge P. Deux accidents ischémiques cérébraux au cours d'une maladie de Horton traitée : Responsabilité de la corticothérapie ? [lettre]. Presse MéD 1994 ; 23 : 449.
22. Peyrade F, Boscagli A, Roa M, Taillan B, Dujardin P. Accident ischémique cérébral précoce après corticothérapie pour maladie de Horton. Rev MéD Interne 1997 ; 18 : 585-6.
23. Ferrandiz D, Joguet R, Yvin JL. Ischémie aiguë du membre supérieur survenant à la phase initiale du traitement corticoïde d'une maladie de Horton. Rev MéD Interne 1999 ; 20 : 87-8.
24. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997 ; 104 : 854-8.
25. Gonzales-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis. Arthritis Rheum 1998 ; 41 : 1497-504.
26. Liozon F, Jauberteau-Marchan MO, Boutros-Toni F, Barrier JH, Dupond JL, Roblot P, et al. Anticorps anticardiolipine et maladie de Horton. Ann MéD Interne 1995 ; 146 : 541-7.
27. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1,990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990 ; 33 : 1122-8.
28. Schneider HA, Weber AA, Ballen PH. The visual prognosis in temporal arteritis. Ann Ophthalmol 1971 ; 3 : 1215-8.
29. Conn DL, Tompkins RB, Nichols WL. Glucocorticoids in the management of vasculitis: A double edged sword? J Rheumatol 1988 ; 15 : 1181-3.
30. Nordborg E, Bengtsson BA. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. Br Med J 1989 ; 299 : 549-50.
31. Graham E, Holland A, Avery A, Russel RW. Prognosis in giant cell arteritis. Br Med J 1981 ; 282 : 269-71.
32. Duhaut P, Pinede L, Demolombe-Rague S, Loire R, Seydoux D, Ninet J, et al. Giant cell arteritis and cardiovascular risk factors. Arthritis Rheum 1998 ; 11 : 1960-5.
33. Espinoza LR, Jara LJ, Silveira LH, Martinez-Osuna P, Zwolinska JB, Kneer C, et al. Anticardiolipin antibodies in polymyalgia rheumatica - Giant cell arteritis: Association with severe vascular complications. Am J Med 1991 ; 90 : 474-8.
34. Liozon E, Roussel V, Roblot P, Liozon F, Preud'homme JL, Loustaud V, et al. Absence of anti-β2 glycoprotein I antibodies in giant cell arteritis: A study of 45 biopsy-proven cases. Br J Rheumatol 1998 ; 37 : 1129-31.
35. Hulin C, Hachulla E, Michon-Pasturel U, Hatron PY, Masy E, Gillot JM, et al. Prévalence des anticorps antiphospholipides dans la maladie de Horton et dans la pseudopolyarthrite rhizomélique. Rev MéD Interne 1999 ; 20 : 659-63.
36. Chevalet P, Pottier P, Planchon B, Pottier MA, Magadur G, Hamidou M, et al. Protocole SNFMI multicentrique sur l'utilisation des bolus IV de méthylprednisolone à la période d'attaque de la maladie de Horton simple : Résultats définitifs à un an (164 patients). Rev MéD Interne 1998 ; 19 Suppl 1 : 87s.
37. Liberman E, Heuser E, Gilchrist GS, Donnel GN, Landing GH. Thrombosis, nephrosis and corticosteroid therapy. J Pediatr 1968 ; 73 : 320-8.
38. Mukherjee AP, Toh BH, Chan GL, Lau KS, White JC. Vascular complications in nephrotic syndrome: Relationship to steroid therapy and accelerated thromboplastin generation. Br Med J 1970 ; 4 : 273-6.
39. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 1970 ; 7 : 212-6.